Calquence(Acalabrutinib)

[Description of Calquence(Acalabrutinib)]

Calquence is a Bruton tyrosine kinase (BTK) inhibitor, which can block the enzymes needed by cancer cells for proliferation and diffusion. It brings hope for the treatment of patients with MCL(Mantle Cell Lymphoma (MCL). In a one-arm trial involving 124 MCL patients, the proportion of patients with complete remission and partial remission after Calquence treatment was evaluated. The results showed that 81% of the patients had corresponding treatment for Calquence, of which 40% had complete remission and 41% had partial remission. Based on this excellent curative effect data, FDA accelerated the approval of the drug’s marketing.

Calquence(Acalabrutinib)_ Hong Kong Jimin Pharmaceutical

[Indications of Calquence(Acalabrutinib)]

Calquence is a kinase inhibitor, which is suitable for receiving at least one treatment for adult patients with mantle cell lymphoma (MCL).

[Calquence(Acalabrutinib) specification]

This product is a capsule, 100mg/60 capsules.

[usage and dosage of Calquence(Acalabrutinib)]

(1) Take one capsule twice a day.

(2) Advise patients not to break, open or chew capsules.

(3) Interruption of treatment, reduction of dosage, or termination of treatment toxicity.

[Common Adverse Reactions of Calquence(Acalabrutinib)]

The most common adverse reactions (reported in ≥ 20% of patients) are anemia, thrombocytopenia, headache, neutropenia, diarrhea, fatigue, muscle pain, and bruising.

[Calquence(Acalabrutinib) Warning and Precautions]

(1) Bleeding: Monitor bleeding and handle it locally.

(2) Infection: Monitor the signs and symptoms of infection of patients and treat them if necessary.

(3) Hypocytopenia: Monitor the complete blood cell count every month during the treatment.

(4) The second primary frontal disease: other malignant diseases, including skin cancer and other cancers, occur among patients. Advise patients to use protection against sunlight.

(5) Atrial fibrillation and flutter: Monitor atrial fibrillation and atrial flutter and handle them as appropriate.

[Calquence(Acalabrutinib) Drug Interaction]

(1) CYP3A inhibitors: Avoid co-administration with strong CYP3A inhibitors. Dose adjustment may be suggested.

(2) CYP3A inducer: Avoid co-administration with strong CYP3A inducer. Dose adjustment may be recommended.

(3) Hypogastric drugs: Avoid individual administration with proton pump inhibitors (PPIs). Interlaced with H2 receptor antagonists and antacids.

[Calquence(Acalabrutinib) is used by special people]

Breastfeeding: Women are advised not to breastfeed.